Two Sigma Investments LP Decreases Position in Iqvia Holdings Inc (IQV)

Two Sigma Investments LP trimmed its holdings in Iqvia Holdings Inc (NYSE:IQV) by 63.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,958 shares of the medical research company’s stock after selling 107,524 shares during the quarter. Two Sigma Investments LP’s holdings in Iqvia were worth $7,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. CENTRAL TRUST Co increased its stake in shares of Iqvia by 1,150.0% in the 4th quarter. CENTRAL TRUST Co now owns 375 shares of the medical research company’s stock worth $44,000 after acquiring an additional 345 shares in the last quarter. Berman Capital Advisors LLC bought a new position in shares of Iqvia in the 4th quarter worth about $46,000. ERTS Wealth Advisors LLC bought a new position in shares of Iqvia in the 4th quarter worth about $46,000. Financial Gravity Companies Inc. bought a new position in shares of Iqvia in the 4th quarter worth about $59,000. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of Iqvia by 44,777.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,140,389 shares of the medical research company’s stock worth $61,000 after acquiring an additional 7,124,478 shares in the last quarter. Institutional investors own 90.99% of the company’s stock.

Shares of NYSE IQV opened at $141.65 on Monday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 1.57. The stock has a market cap of $28.02 billion, a PE ratio of 27.67, a P/E/G ratio of 1.72 and a beta of 0.85. Iqvia Holdings Inc has a 52-week low of $91.57 and a 52-week high of $145.16.



Iqvia (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.03. The firm had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.40 EPS. On average, equities research analysts forecast that Iqvia Holdings Inc will post 5.87 earnings per share for the current fiscal year.

IQV has been the subject of several research reports. Goldman Sachs Group upgraded shares of Iqvia from a “buy” rating to a “conviction-buy” rating in a research note on Friday, January 11th. Jefferies Financial Group upgraded shares of Iqvia from a “hold” rating to a “buy” rating and raised their price objective for the company from $136.00 to $150.00 in a research note on Friday, January 18th. Wells Fargo & Co raised their price objective on shares of Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a research note on Tuesday, February 19th. UBS Group set a $170.00 price objective on shares of Iqvia and gave the company a “buy” rating in a research note on Friday, February 15th. Finally, Argus raised their price objective on shares of Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $146.88.

In related news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $140.80, for a total value of $569,462,784.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider W Richard Staub sold 27,025 shares of the firm’s stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $140.54, for a total transaction of $3,798,093.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,075,345 shares of company stock worth $573,760,078. Insiders own 6.00% of the company’s stock.

WARNING: “Two Sigma Investments LP Decreases Position in Iqvia Holdings Inc (IQV)” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/03/25/two-sigma-investments-lp-decreases-position-in-iqvia-holdings-inc-iqv.html.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: Certificate of Deposit (CD)

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.